Can you take Tylenol and Z-Pak together?
By
Dr Milena Locci de Oliveira (PhD)
Author bio
Dr Milena Locci de Oliveira is a Pharmacist and Doctor of Philosophy in Sciences from the University of São Paulo (USP). She has experience in microbiology, analytical toxicology, and clinical pharmacokinetics. She writes and reviews content on these topics.
Dr Milena’s Highlights:
-PhD in Sciences, University of São Paulo, Brazil, 2019.
-University College London (UCL) – Semester of remote collaboration in the areas of Pharmacometrics and Population Pharmacokinetics, 2018.
-Bachelor in Biochemical Pharmacy, University of São Paulo, Brazil, 2013.
“Science can be translated, and it is essential that everyone has access to quality information to make informed decisions” – Dr Milena Oliveira, PhD.
Professional Experience:
With a decade-long career as a researcher, Dr Milena has amassed extensive experience in conducting research projects in microbiology, analytical toxicology, and clinical pharmacokinetics.
Her expertise also extends to the preparation of technical and scientific reports, literature reviews, data analysis, and scientific communication, both oral and written.
Dr Milena has served as a Clinical Pharmacist, providing expert supervision and guidance to teams during the challenging times of the COVID-19 pandemic, particularly in the ICUs of two reference hospitals for patient hospitalization.
In her most recent role, Dr Milena worked on the implementation of the deliberatives of the São Paulo State Government Pharmaceutical Assistance Coordination. These decisions were aimed at ensuring medication access within the Unified Health System.
A widely multidisciplinary background enabled Dr Milena to become a professional capable of integrating scientific knowledge into private initiatives, education, and healthcare, delivering consistent services in patient safety and population health.
Professional Memberships & Affiliations:
Dr Milena Oliveira is a member of the Regional Council of Pharmacy of the State of São Paulo, Brazil.
Education:
-PhD in Sciences, University of São Paulo, Brazil, 2019.
-University College London (UCL) – Semester of remote collaboration, 2018.
-Bachelor in Biochemical Pharmacy, University of São Paulo, Brazil, 2013.
Relevant Published Work & Citations:
Oliveira ML de, Rocha A, Nardotto GHB, Pippa LF, Simões BP, Lanchote VL. Analysis of daunorubicin and its metabolite daunorubicinol in plasma and urine with application in the evaluation of total, renal and metabolic formation clearances in patients with acute myeloid leukemia. Journal of Pharmaceutical and Biomedical Analysis. Nov 2020. 191:113-124.
Abstracts. CPT: Pharmacometrics & Systems Pharmacology. 2020 Nov; 9 (S1).
Pippa LF, Oliveira ML de, Rocha A, de Andrade JM, Lanchote VL. Total, renal and hepatic clearances of doxorubicin and formation clearance of doxorubicinol in patients with breast cancer: Estimation of doxorubicin hepatic extraction ratio. Journal of Pharmaceutical and Biomedical Analysis. 2020 Jun 5; 185:113-231.
Godoy ALPC, De Jesus C, De Oliveira ML, Rocha A, Pereira MPM, Larangeira DF, Lanchote VL, Barrouin-Melo SM. Determination of Allopurinol and Oxypurinol in Dogs Plasma by High-Performance Liquid Chromatography with an Ultraviolet Detector: Application for Pharmacokinetic Studies. J Chromatogr Sep Tech. 2017; 8 (4).
Clímaco EC, Oliveira ML de, Pitondo-Silva A, Oliveira MG, Medeiros M, Lincopan N, et al. Clonal complexes 104, 109 and 113 playing a major role in the dissemination of OXA-carbapenemase-producing Acinetobacter baumannii in Southeast Brazil. Infection, Genetics and Evolution. 2013 Oct;19:127–33.
Conference Papers:
Oliveira, M. L.; NARDOTTO, G. H. B.; PIPPA, L. F.; ROCHA, A.; SIMOES, B. P.; LANCHOTE, V. L. . Daunorubicin metabolism and urinary excretion in patients with acute myeloid leukemia. In: 84th Annual Meeting of the German Society for Experimental and Clinical Pharmacology and Toxicology (DGPT) and the 20th Annual Meeting of the Association of the Clinical Pharmacology Germany (VKliPha), 2018, Göttingen. Naunyn-Schmiedeberg’s Arch Pharmacol, 2018. v. 391. p. S76-S76.
Oliveira, M. L.; NARDOTTO, G. H. B. ; ROCHA, A. ; SIMOES, B. P. ; LANCHOTE, V. L. . The low contribution of urinary excretion in the elimination of daunorubicin and its metabolite daunorubicinol in patients with acute myeloid leukemia. In: 49th Brazilian Congress of Pharmacology and Experimental Therapeutics., 2017, Ribeirão Preto. Livro de Resumos, 2017. p. 64-64.
Oliveira, M. L.; PIPPA, L. F. ; ROCHA, A. ; SIMOES, B. P. ; LANCHOTE, V. L. . Quantification of daunorubicin and its metabolite daunorubicinol in human plasma by LC-MS/MS. In: I International Meeting of Environmental Health and Toxicology (IMEHTOX), 2016, Ribeirão Preto. Livro de Resumos, 2016.
Oliveira, M. L.; Clímaco, E.C. ; OLIVEIRA, M. G. ; Lincopan, N. ; Darini A.L.C. . PFGE typing of Carbapenem-Resistant Acinetobacter baumannii isolated from different University Hospitals. In: V International Postgraduate and Research Symposium, 2012.
Clímaco, E.C. ; SILVA, A. P. ; Oliveira, M. L. ; OLIVEIRA, M. G. ; Lincopan, N. ; Darini A.L.C. Relação clonal entre linhagens de Acinetobacter baumannii produtoras de carbapenemases da família OXA em quatro hospitais no Brasil. In: XXI Latin American Congress of Microbiology, 2012, Santos. XXI Latin American Congress of Microbiology, 2012.
Oliveira, M. L.; Clímaco, E.C. ; OLIVEIRA, M. G. ; Darini A.L.C. . Dissemintion of OXA carbapenemases genes in carbapenem-resistant Acinetobacter baumannii in University Hospital of Juiz de Fora, MG. In: 8th CIFARP – International Congress of Pharmaceutical Sciences, 2011, Ribeirão Preto.
Clímaco, E.C. ; Oliveira, M. L. ; OLIVEIRA, M. G. ; Darini A.L.C. . Avaliação do sequenciamento parcial do gene rpoB e de seus flanqueadores para identificação de espécies de Acinetobacter na rotina laroratorial. In: 2° International Symposium on Clinical Microbiology, 2010, Florianópolis.
You can view some of Dr Milena’s work below and links to her professional profile.
Linkedin: https://www.linkedin.com/in/dra-milena-locci-de-oliveira-28986042/?locale=en_US
ResearchGate: https://www.researchgate.net/profile/Milena-Oliveira-6
Escavador: https://www.escavador.com/sobre/5394254/milena-locci-de-oliveira
Lattes: https://buscatextual.cnpq.br/buscatextual/busca.do
Scopus: https://www.scopus.com/authid/detail.uri?authorId=57199779361
Scholar: https://scholar.google.com/citations?view_op=list_works&hl=pt-BR&user=1YUBDIQAAAAJ
Can you take Tylenol and Z-Pak together?
Yes, you can take Tylenol and Z-Pak together. Tylenol contains Acetaminophen, which is considered the safest painkiller to be used with medications that have more interactions with other drugs, like antibiotics, antidepressants, antihypertensives, etc (1).
The combination of Z-Pak (Azithromycin) and Acetaminophen does not have negative effects on your body and is frequently used worldwide (1,2). However, Tylenol may not help relieve your pain if it is severe.
There are some other painkillers like Non-steroidal anti-inflammatory drugs that only manage pain, but also manage inflammation that Tylenol can’t help you with.
You can use NSAIDs like Ibuprofen, but you need to talk to your healthcare provider before using it concomitantly with Azithromycin since NSAIDs have more chances of reacting with other medications.
This is exactly why Tylenol (Acetaminophen) is the only painkiller which is considered safe with medications like antibiotics.
Potential benefits of taking Tylenol and Z-Pak together
Taking Tylenol and Z-Pak together may offer potential benefits for individuals dealing with certain health conditions. Tylenol can help manage any discomfort or fever associated with infections while Z-Pak works to combat the underlying bacterial infection (1,2).
This combination can help individuals experience relief from both the symptoms and the cause of their health issues simultaneously.
Who should not take Tylenol and Z-Pak together?
Certain individuals should avoid taking Tylenol and Z-Pak together due to potential interactions or health risks.
People who have specific health conditions or medical histories may be more susceptible to adverse effects from the combination of these medications. For example: (1,2)
- Liver conditions: Tylenol is processed in the liver, and individuals with liver conditions or a history of liver problems should be cautious about taking it with other medications, including Z-Pak.
- Allergies or sensitivities: Some individuals may be allergic to either Tylenol or Z-Pak or have experienced adverse reactions to similar medications in the past.
- Drug interactions: Z-Pak and Tylenol can interact with other medications an individual is taking, potentially leading to harmful side effects or reducing the effectiveness of either medication.
- Kidney problems: While Tylenol is generally considered safe for people with kidney issues when taken at recommended doses, combining it with certain antibiotics, like Z-Pak, might require dose adjustments.
- Pre-existing medical conditions: People with certain medical conditions, such as heart problems, asthma, or gastrointestinal disorders, should seek medical advice before combining Tylenol and Z-Pak.
It is essential for individuals with any underlying health conditions or concerns to consult their healthcare provider before taking these medications together.
Your doctor can evaluate their medical history, current medications, and overall health status to determine the appropriate treatment plan and ensure their safety and well-being.
Was this helpful?
References
1.-
LABEL: TYLENOL REGULAR STRENGTH- acetaminophen tablet, film coated. DailyMed [Internet]. Available from: https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?setid=511536b2-6cbd-463e-b2db-6feec474cf6b&type=pdf
2.-
LABEL: AZITHROMYCIN tablet, film-coated. DailyMed [Internet]. Available from: https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?setid=5dca5a11-3c02-4a51-a35d-f91f37b8e00c&type=pdf
